[1]
Ruiz-Torres, V.; Encinar, J.A.; Herranz-López, M.; Pérez-Sánchez, A.; Galiano, V.; Barrajón-Catalán, E.; Micol, V. An updated review on marine anticancer compounds: The use of virtual screening for the discovery of small-molecule cancer drugs. Molecules, 2017, 22(7), 1037.
[2]
Bhurgri, Y. Karachi cancer registry data-Implications for the national cancer control program of Pakistan. Asian Pac. J. Cancer Prev., 2004, 5(1), 77-82.
[3]
McCarthy, C.M.; Hamill, J.B.; Kim, H.M.; Qi, J.; Wilkins, E.; Pusic, A.L. Impact of bilateral prophylactic mastectomy and immediate reconstruction on health-related quality of life in women at high risk for breast carcinoma: Results of the mastectomy reconstruction outcomes consortium study. Ann. Surg. Oncol., 2017, 24(9), 2502-2508.
[4]
Fracasso, G.; Marzola, P.; Accardo, A. Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Int. J. Nanomedicine, 2017, 12, 501.
[5]
Haldosén, L.A.; Zhao, C.; Dahlman-Wright, K. Estrogen receptor beta in breast cancer. Mol. Cell. Endocrinol., 2014, 382(1), 665-672.
[6]
Yam, C.; Mani, S.A.; Moulder, S.L. Targeting the molecular subtypes of triple negative breast cancer: Understanding the diversity to progress the field. Oncologist, 2017, 22(9), 1086-1093.
[7]
Denkert, C.; Liedtke, C.; Tutt, A.; von Minckwitz, G. Molecular alterations in triple-negative breast cancer - The road to new treatment strategies. Lancet, 2017, 389, 2430-2442.
[8]
Wahba, H.A.; El-Hadaad, H.A. Current approaches in treatment of triple-negative breast cancer. Cancer Biol. Med., 2015, 12(2), 106.
[9]
Abdelbadie, A.; Adam, E.A.; Abdelrahman, M. The effect of PT link and waterbath antigenic retrieval procedures on the expression of common receptors in breast cancer cases. Sudan J. Med. Sci., 2017, 12(1), 1-8.
[10]
Katzenellenbogen, B.S.; Zhao, Y.; Laws, M.J.; Guillen, V.S.; Ziegler, Y.; Min, J.; Oesterreich, S. Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Res., 2017, 77(20), 5602-5613.
[11]
Kurebayashi, J. Biological and clinical significance of HER2 overexpression in breast cancer. Breast Cancer, 2001, 8(1), 45-51.
[12]
Park, S.; Nedrow, J.R.; Josefsson, A.; Sgouros, G. Human HER2 overexpressing mouse breast cancer cell lines derived from MMTV. f. HuHER2 mice: Characterization and use in a model of metastatic breast cancer. Oncotarget, 2017, 8(40), 68071.
[13]
Das, J.R.; Fryar-Tita, E.B.; Zhou, Y.; Green, S.; Southerland, W.M.; Bowen, D. Sequence-dependent administration of 5-fluorouracil maintains methotrexate antineoplastic activity in human estrogen-negative breast cancer and protects against methotrexate cytotoxicity in human bone marrow. Anticancer Res., 2007, 27(6B), 3791-3799.
[14]
Ringhieri, P.; Mannucci, S.; Conti, G.; Nicolato, E.; Fracasso, G.; Marzola, P.; Accardo, A. Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells. Int. J. Nanomedicine, 2017, 12, 501.
[15]
Kadow, J.F.; Meanwell, N.A.; Eastman, K.J.; Yeung, K.S.; DelMonte, A.J. Chemistry in the Pharmaceutical Industry. In: Handbook of Industrial Chemistry and Biotechnology; , 2017. Springer, pp. 531-579.
[16]
Kumar, D.; Sharma, P.; Singh, H.; Nepali, K.; Gupta, G.K.; Jain, S.K.; Ntie-Kang, F. The medicinal potential of synthetic and naturally occurring anticancer pyran scaffolds. Cell, 2017, 5, A498.
[17]
Potočňák, I.; Vranec, P.; Farkasová, V.; Sabolová, D.; Vataščinová, M.; Kudláčová, J.; Radojević, I.D.; Čomić, L.R.; Markovic, B.S.; Volarevic, V.; Arsenijevic, N. Low-dimensional compounds containing bioactive ligands. Part VI: Synthesis, structures, in vitro DNA binding, antimicrobial and anticancer properties of first row transition metal complexes with 5-chloro-quinolin-8-ol. J. Inorg. Biochem., 2016, 154, 67-77.
[18]
Kaushik, V.; Azad, N.; Yakisich, J.S.; Iyer, A.K.V. Antitumor effects of naturally occurring cardiac glycosides convallatoxin and peruvoside on human ER+ and triple-negative breast cancers. Cell Death Discov., 2017, 3, 17009.
[19]
Ramamoorthy, M.D.; Kumar, A.; Ayyau, M.; Dhiraviam, K.N. Reserpine induces apoptosis and cell cycle arrest in hormone independent prostate cancer cells through mitochondrial membrane potential failure. Anticancer. Agents Med. Chem., 2018, 18(9), 1313-1322.
[20]
Abdelfatah, S.A.; Efferth, T. Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells. Phytomedicine, 2015. 22(2015), 308-318
[21]
Nakamura, Y.; Yoshida, C.; Murakami, A.; Ohigashi, H.; Osawa, T.; Uchida, K. Zerumbone, a tropical ginger sesquiterpene, activates phase II drug metabolizing enzymes. FEBS Lett., 2004, 572(1-3), 245-250.
[22]
Yen, G.C.; Tsai, C.M.; Lu, C.C.; Weng, C.J. Recent progress in natural dietary non-phenolic bioactives on cancers metastasis. J. Food Drug Anal., 2018, 26(3), 940-964.
[23]
Eid, E.E.; Abdul, A.B.; Suliman, F.E.O.; Sukari, M.A.; Rasedee, A.; Fatah, S.S. Characterization of the inclusion complex of zerumbone with hydroxypropyl-β-cyclodextrin. Carbohydr. Polym., 2011, 83(4), 1707-1714.
[24]
Ma, J.W.; Hung, C.M.; Lin, Y.C.; Ho, C.T.; Kao, J.Y.; Way, T.D. Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget, 2016, 7(37), 58915.
[25]
Velaga, R.; Sugimoto, M. Future Paradigm of Breast Cancer Resistance and Treatment. In: Resistance to Targeted Therapies in Breast Cancer; , 2017. Springer, Cham, pp. 155-178.
26
2